Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Changes in brain function during administration of venlafaxine or placebo to normal subjects.

Leuchter AF, Cook IA, DeBrota DJ, Hunter AM, Potter WZ, McGrouther CC, Morgan ML, Abrams M, Siegman B.

Clin EEG Neurosci. 2008 Oct;39(4):175-81.

PMID:
19044214
2.

Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.

Hunter AM, Leuchter AF, Cook IA, Abrams M.

Acta Psychiatr Scand. 2010 Dec;122(6):461-9. doi: 10.1111/j.1600-0447.2010.01560.x.

PMID:
20384600
3.
4.

Changes in brain function of depressed subjects during treatment with placebo.

Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M.

Am J Psychiatry. 2002 Jan;159(1):122-9.

PMID:
11772700
5.

QEEG Theta Cordance in the Prediction of Treatment Outcome to Prefrontal Repetitive Transcranial Magnetic Stimulation or Venlafaxine ER in Patients With Major Depressive Disorder.

Bares M, Brunovsky M, Novak T, Kopecek M, Stopkova P, Sos P, Höschl C.

Clin EEG Neurosci. 2015 Apr;46(2):73-80. doi: 10.1177/1550059413520442. Epub 2014 Apr 7.

PMID:
24711613
6.

Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo.

Hunter AM, Leuchter AF, Morgan ML, Cook IA, Abrams M, Siegman B, DeBrota DJ, Potter WZ.

Neuropsychopharmacology. 2005 Apr;30(4):792-9.

7.

Neurophysiologic effects of repeated exposure to antidepressant medication: are brain functional changes during antidepressant administration influenced by learning processes?

Hunter AM, Cook IA, Abrams M, Leuchter AF.

Med Hypotheses. 2013 Dec;81(6):1004-11. doi: 10.1016/j.mehy.2013.09.016. Epub 2013 Sep 17.

8.

Midline and right frontal brain function as a physiologic biomarker of remission in major depression.

Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF.

Psychiatry Res. 2009 Nov 30;174(2):152-7. doi: 10.1016/j.pscychresns.2009.04.011. Epub 2009 Oct 22.

9.

Early changes in prefrontal activity characterize clinical responders to antidepressants.

Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M, Rosenberg S, Uijtdehaage SH.

Neuropsychopharmacology. 2002 Jul;27(1):120-31.

10.

Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.

Hunter AM, Muthén BO, Cook IA, Leuchter AF.

J Psychiatr Res. 2010 Jan;44(2):90-8. doi: 10.1016/j.jpsychires.2009.06.006. Epub 2009 Jul 24.

11.

Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder.

Bares M, Brunovsky M, Kopecek M, Novak T, Stopkova P, Kozeny J, Sos P, Krajca V, Höschl C.

Eur Psychiatry. 2008 Aug;23(5):350-5. doi: 10.1016/j.eurpsy.2008.03.001. Epub 2008 May 2.

PMID:
18450430
13.

Does prior antidepressant treatment of major depression impact brain function during current treatment?

Hunter AM, Cook IA, Leuchter AF.

Eur Neuropsychopharmacol. 2012 Oct;22(10):711-20. doi: 10.1016/j.euroneuro.2012.02.005. Epub 2012 Mar 23.

PMID:
22445212
14.

Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial.

van Kerkhoven LA, Laheij RJ, Aparicio N, De Boer WA, Van den Hazel S, Tan AC, Witteman BJ, Jansen JB.

Clin Gastroenterol Hepatol. 2008 Jul;6(7):746-52; quiz 718. doi: 10.1016/j.cgh.2008.02.051. Epub 2008 Apr 18.

PMID:
18424191
15.

Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.

Leuchter AF, McGough JJ, Korb AS, Hunter AM, Glaser PE, Deldar A, Durell TM, Cook IA.

J Psychiatr Res. 2014 Jul;54:11-8. doi: 10.1016/j.jpsychires.2014.03.009. Epub 2014 Mar 27.

PMID:
24726639
16.

A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, Bisaga A, Sullivan MA, Carpenter KM.

Addiction. 2013 Jun;108(6):1084-94. doi: 10.1111/add.12108. Epub 2013 Mar 21.

17.

Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study.

Bares M, Brunovsky M, Kopecek M, Stopkova P, Novak T, Kozeny J, Höschl C.

J Psychiatr Res. 2007 Apr-Jun;41(3-4):319-25. Epub 2006 Aug 4.

PMID:
16889798
18.

A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.

Luthringer R, Toussaint M, Schaltenbrand N, Bailey P, Danjou PH, Hackett D, Guichoux JY, Macher JP.

Psychopharmacol Bull. 1996;32(4):637-46.

PMID:
8993085
19.

Venlafaxine extended-release: a review of its use in the management of major depression.

Wellington K, Perry CM.

CNS Drugs. 2001;15(8):643-69. Review.

PMID:
11524036
20.

Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.

Hunter AM, Ravikumar S, Cook IA, Leuchter AF.

Acta Psychiatr Scand. 2009 Apr;119(4):266-73. doi: 10.1111/j.1600-0447.2008.01305.x. Epub 2008 Dec 9.

PMID:
19077131

Supplemental Content

Support Center